Iridex Corporation’s Upcoming Financial Results Announcement
Iridex Corporation (NASDAQ: IRIX), a global leader recognized for its innovative laser-based medical systems and devices for treating glaucoma and retinal diseases, is gearing up to announce its financial results for the fourth quarter and full year of 2024. The official release will take place after the trading session concludes on March 27, 2025.
Details of the Upcoming Event
The management team at Iridex will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET to discuss these results. Investors and analysts are encouraged to participate by calling +1-888-596-4144 and entering the conference ID: 5685253. Additionally, they can tune in to a live and recorded webcast available on the ‘Event Calendar’ portion of the Company’s investor page online.
About Iridex Corporation
Founded with the aim of improving ocular health, Iridex Corporation specializes in the development, production, and marketing of advanced laser-based medical technologies. These systems play a crucial role in treating severe eye conditions, predominantly glaucoma and diabetic macular edema (DME). A distinctive feature of Iridex’s offerings is the proprietary MicroPulse technology, renowned for its efficacy and safety in delivering targeted treatments for serious eye diseases.
Distribution and Reach
Iridex has successfully established a robust distribution network, ensuring its products reach doctors and healthcare facilities in over 100 countries worldwide. The Company utilizes a direct sales force in the United States while working with independent distributors globally, thereby facilitating access to its cutting-edge medical technologies.
Innovative Technology and Products
Iridex’s comprehensive line of products addresses a range of eye disorders, focusing mainly on glaucoma and diabetic macular edema. Each solution is designed to be user-friendly yet effective, helping healthcare providers deliver superior patient care. The dedication to innovation is evident in the development of the MicroPulse technology, which differentiates Iridex from its competitors by offering a safer and more effective treatment alternative.
Commitment to Investors
The forthcoming financial results presentation is not just a routine disclosure; it symbolizes Iridex’s commitment to transparency and shareholder engagement. Investors are likely to gain valuable insights into the Company’s operational performance and strategic direction following the release.
Contact Information
For further inquiries or additional details, investors can reach out to Philip Taylor at the Gilmartin Group. His email address is investors@iridex.com. The Company prioritizes investor relations and is always eager to provide clarity regarding its business operations.
Frequently Asked Questions
What is the date of Iridex Corporation's earnings release?
The earnings release for the fourth quarter and full year 2024 is scheduled for March 27, 2025.
How can investors participate in the conference call?
Investors can join the call by dialing +1-888-596-4144 and entering the conference ID: 5685253.
What type of products does Iridex Corporation offer?
Iridex specializes in laser-based medical systems and delivery devices for treating glaucoma and retinal diseases.
How does Iridex distribute its products?
The Company utilizes a direct sales force in the U.S. and partners with independent distributors internationally.
Where can I find more information about Iridex Corporation?
More details can be found on the Iridex Corporation website at www.iridex.com.
